185 related articles for article (PubMed ID: 34926500)
1. Cost-Effectiveness of Conbercept vs. Ranibizumab for Age-Related Macular Degeneration, Diabetic Macular Edema, and Pathological Myopia: Population-Based Cohort Study and Markov Model.
Cui Z; Zhou W; Chang Q; Zhang T; Wang H; Meng X; Liu Y; Yan H
Front Med (Lausanne); 2021; 8():750132. PubMed ID: 34926500
[No Abstract] [Full Text] [Related]
2. Conbercept for Treatment of Neovascular Age-Related Macular Degeneration and Visual Impairment due to Diabetic Macular Edema or Pathologic Myopia Choroidal Neovascularization: A Systematic Review and Meta-Analysis.
Zhou P; Zheng S; Wang E; Men P; Zhai S
Front Pharmacol; 2021; 12():696201. PubMed ID: 34712132
[No Abstract] [Full Text] [Related]
3. Cost-effectiveness of intravitreal conbercept versus other treatments for wet age-related macular degeneration.
Chen R; Wu B
Ann Transl Med; 2020 Aug; 8(15):939. PubMed ID: 32953739
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration.
Hernandez-Pastor LJ; Ortega A; Garcia-Layana A; Giraldez J
Clin Ther; 2008 Dec; 30(12):2436-51. PubMed ID: 19167602
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of ranibizumab in the treatment of visual impairment due to diabetic macular edema.
Haig J; Barbeau M; Ferreira A
J Med Econ; 2016 Jul; 19(7):663-71. PubMed ID: 26882365
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration.
Hernández-Pastor LJ; Ortega A; García-Layana A; Giráldez J
Graefes Arch Clin Exp Ophthalmol; 2010 Apr; 248(4):467-76. PubMed ID: 19669678
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Treatment: Analysis From the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial.
Ross EL; Hutton DW; Stein JD; Bressler NM; Jampol LM; Glassman AR;
JAMA Ophthalmol; 2016 Aug; 134(8):888-96. PubMed ID: 27280850
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of ranibizumab versus aflibercept in the treatment of visual impairment due to diabetic macular edema: a UK healthcare perspective.
Régnier SA; Malcolm W; Haig J; Xue W
Clinicoecon Outcomes Res; 2015; 7():235-47. PubMed ID: 25999748
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of myopia management: A systematic review.
Agyekum S; Chan PP; Zhang Y; Huo Z; Yip BHK; Ip P; Tham CC; Chen LJ; Zhang XJ; Pang CP; Yam JC
Front Public Health; 2023; 11():1093836. PubMed ID: 36923029
[TBL] [Abstract][Full Text] [Related]
10. Comparison of 12-month therapeutic effect of conbercept and ranibizumab for diabetic macular edema: a real-life clinical practice study.
Xu Y; Rong A; Xu W; Niu Y; Wang Z
BMC Ophthalmol; 2017 Aug; 17(1):158. PubMed ID: 28841827
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of ranibizumab and aflibercept to treat diabetic macular edema from a US perspective: analysis of 2-year Protocol T data.
Holekamp N; Duff SB; Rajput Y; Garmo V
J Med Econ; 2020 Mar; 23(3):287-296. PubMed ID: 31502893
[No Abstract] [Full Text] [Related]
12. Intravitreal Ranibizumab for the Treatment of Visual Impairment Due to Choroidal Neovascularization Associated with Rare Diseases: Cost-Effectiveness in the UK.
McCarthy G; Fenu E; Bennett N; Almond C
Adv Ther; 2019 Mar; 36(3):632-644. PubMed ID: 30726549
[TBL] [Abstract][Full Text] [Related]
13. Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies.
Carrasco J; Pietsch GA; Nicolas MP; Koerber C; Bennison C; Yoon J
Adv Ther; 2020 Jan; 37(1):300-315. PubMed ID: 31728825
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial.
Mitchell P; Annemans L; Gallagher M; Hasan R; Thomas S; Gairy K; Knudsen M; Onwordi H
Br J Ophthalmol; 2012 May; 96(5):688-93. PubMed ID: 22399690
[TBL] [Abstract][Full Text] [Related]
15. Five-Year Cost-effectiveness of Intravitreous Ranibizumab Therapy vs Panretinal Photocoagulation for Treating Proliferative Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial.
Hutton DW; Stein JD; Glassman AR; Bressler NM; Jampol LM; Sun JK;
JAMA Ophthalmol; 2019 Dec; 137(12):1424-1432. PubMed ID: 31647496
[TBL] [Abstract][Full Text] [Related]
16. Cost-Utility Analysis of VEGF Inhibitors for Treating Neovascular Age-Related Macular Degeneration.
Brown GC; Brown MM; Rapuano S; Boyer D
Am J Ophthalmol; 2020 Oct; 218():225-241. PubMed ID: 32565050
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of intravitreal aflibercept in the treatment of diabetic macular edema in China.
Ming J; Zhang Y; Xu X; Zhao M; Wang Y; Chen Y; Zhang F; Wang J; Liu J; Zhao X; Han R; Hu S
J Comp Eff Res; 2020 Feb; 9(3):161-175. PubMed ID: 31904267
[No Abstract] [Full Text] [Related]
18. Cost-utility of ranibizumab versus aflibercept for treating Greek patients with visual impairment due to diabetic macular edema.
Kourlaba G; Relakis J; Mahon R; Kalogeropoulou M; Pantelopoulou G; Kousidou O; Maniadakis N
Cost Eff Resour Alloc; 2016; 14():7. PubMed ID: 27081372
[TBL] [Abstract][Full Text] [Related]
19. Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema.
Fong AH; Lai TY
Clin Interv Aging; 2013; 8():467-83. PubMed ID: 23766636
[TBL] [Abstract][Full Text] [Related]
20. Cost-Minimization Analysis of Ranibizumab Versus Aflibercept for Treating Saudi Patients With Visual Impairment Owing to Age-Related Macular Degeneration or Diabetic Macular Edema.
El-Dahiyat F; Eljilany I
Value Health Reg Issues; 2020 Sep; 22():23-26. PubMed ID: 32247191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
